What is Zacks Research’s Forecast for Chemours Q1 Earnings?

The Chemours Company (NYSE:CC – Free Report) – Equities research analysts at Zacks Research reduced their Q1 2027 earnings per share (EPS) estimates for Chemours in a report issued on Monday, November 16th. Zacks Research analyst Team now forecasts that the specialty chemicals company will post earnings per share of $0.21 for the quarter, down from their previous forecast of $0.40. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Chemours’ FY2027 earnings at $1.71 EPS and FY2028 earnings at $1.98 EPS.

Chemours (NYSE:CC – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). Chemours had a positive return on equity of 76.52% and a negative net margin of 2.64%. The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the previous year, the firm earned $0.40 EPS. The business’s revenue for the quarter was up 3.0% on a year-over-year basis.

Several other research analysts also recently issued reports on CC. Mizuho downgraded shares of Chemours from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $18.00 to $15.00 in a research note on Wednesday, October 14th. Barclays initiated coverage on shares of Chemours in a report on Monday, October 12th. They set an “equal weight” rating and a $16.00 price target on the stock. JPMorgan Chase & Co. reduced their price target on shares of Chemours from $15.00 to $14.00 and set a “neutral” rating for the company in a research report on Monday, November 9th. BMO Capital Markets decreased their price objective on shares of Chemours from $26.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, August 13th. Finally, Truist Financial lowered their price objective on Chemours from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, November 4th. Three research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Chemours currently has a consensus rating of “Hold” and a consensus target price of $17.36.

View Our Latest Analysis on Chemours

Chemours Stock Down 2.5%

NYSE:CC opened at $11.78 on Wednesday. The firm has a market cap of $1.77 billion, a P/E ratio of -11.55 and a beta of 1.47. The company has a debt-to-equity ratio of 24.25, a quick ratio of 0.98 and a current ratio of 1.81. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The firm has a 50-day simple moving average of $13.50 and a two-hundred day simple moving average of $18.09.

Chemours Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Monday, November 16th. Chemours’s dividend payout ratio is presently -34.31%.

Hedge Funds Weigh In On Chemours

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Chemours during the 2nd quarter valued at $477,769,000. Wolf Hill Capital Management LP purchased a new stake in shares of Chemours in the 2nd quarter worth $59,698,056. Goldman Sachs Group Inc. increased its stake in shares of Chemours by 10.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 2,838,890 shares of the specialty chemicals company’s stock worth $38,524,000 after purchasing an additional 276,451 shares in the last quarter. Jefferies Financial Group Inc. raised its holdings in Chemours by 251.8% in the 3rd quarter. Jefferies Financial Group Inc. now owns 2,742,068 shares of the specialty chemicals company’s stock worth $37,210,000 after purchasing an additional 1,962,523 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in Chemours in the 2nd quarter worth $33,353,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours News Roundup

Here’s some of the latest news about CC:

  • Neutral Sentiment: Chemours announced that General Counsel Kristine Wellman will retire and that Amy Rocklin will succeed her, effective January 4, 2027. The planned transition does not include a stated change to strategy or financial outlook. Article: Chemours announces General Counsel retirement and appointment
  • Negative Sentiment: Several law firms reiterated that investors have until December 7, 2026, to seek lead-plaintiff status in a securities class action covering purchases from February 20 through August 4, 2026. The complaint alleges Chemours overstated aftermarket demand for its Opteon refrigerants and maintained 2026 guidance without accounting for sales pulled forward by distributor stocking in 2025. These are allegations, not proven findings, but the case may add legal and reputational uncertainty. Article: Chemours shareholder alert on securities lawsuit
  • Negative Sentiment: Zacks Research cut its estimates for Chemours’ Q1 2027 EPS to $0.21 from $0.40, FY2027 EPS to $1.71 from $2.05, and FY2028 EPS to $1.98 from $2.31. Its “Strong Sell” rating and lower profit forecasts could weigh on sentiment by signaling weaker expected earnings. Article: Zacks Research estimates Chemours’ FY2026 earnings

Chemours Company Profile

(Get Free Report)

The Chemours Company is a global chemicals manufacturer spun off from DuPont in 2015 and headquartered in Wilmington, Delaware. It develops and produces materials used in industries ranging from construction and transportation to electronics and energy. Chemours’ Titanium Technologies business makes titanium dioxide (TiO₂) pigment, sold under the Ti-Pure brand, which is used to add whiteness, brightness and opacity to products such as paints, coatings, plastics and paper. Its Thermal & Specialized Solutions business supplies refrigerants, foam-blowing agents and other specialty fluids, including products marketed under the Opteon and Freon brands.

Recommended Stories

Earnings History and Estimates for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.